Centers | ||
|
|
|
Chulalongkorn University Drug Discovery and Drug Development Research Center (Chula4DR) | EU-OPENSCREEN | Weccome Centre for Anti-Infectives Research |
Chulalongkorn
Drug Discovery and Drug Development Research Center (Chula4DR) was
established in 2017, with the aim to facilitate advancement of academic
drug discovery and drug development research by leveraging innovations
and sciences... Read more |
EU-OPENSCREEN is a multinational, not-for-profit initiative, which
integrates high-capacity screening platforms and chemistry groups across
Europe. The aim of this initiative is to support individual scientists
interested in chemical biology... |
WCAIR brings together the Drug Discovery Unit (DDU) , the Mode of Action group and the Parasitology research groups. With the daily interactions of these groups, parasitology and drug discovery can work together in synergy. This empowers us to create... Read more |
Partnerships |
Events |
Jobs |
Research collaboration and license agreementThe University of Dundee‘s Drug Discovery Unit (DDU) has announced a multi-million-pound partnership with Korean-based Bukwang Pharmaceutical Company in a bid to develop a new drug treatment for Parkinson’s disease. This announcement builds upon... View all Pharma and Academia Consortium Partner to Develop New Drugs in EuropeA consortium of academic institutes from Germany, Britain, Netherlands and Denmark partner with a group of leading pharmaceutical companies which include AstraZeneca, Sanofi, Bayer, UCB , Lundbeck , Merck KGaA, and Janssen which is a JNJ... View all Johns Hopkins BSi Licenses GCPII Assets from EisaiJohns Hopkins Brain Science Institute ("BSi") has taken a non-exclusive license from Eisai to develop new compounds related to Glutamate Carboxypeptidase II (GCP-II) technology. The new compounds developed under this license will be targeted... View all |
No EVENTS for listing |
No Job Posts |
